.Attributes Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of patients along with HER2+ innovative breast cancer as well as energetic or even stable mind metastases revealed steady intracranial activity and wide spread efficiency of T-DXd.